Cancer Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The cancer diagnostics market comprises a broad range of tests, imaging technologies, and tools used to detect, stage, and monitor cancer across multiple cancer types. Despite varying estimates from commercial research firms, the market is broadly positioned in the $130-175 billion range for 2025, with projections extending through the 2030s at compound annual growth rates between 6% and 9%. Different scopes and methodologies used by individual research firms account for the wide range of published estimates.

• •Market size estimates differ significantly across commercial research firms based on product scope and geographic coverage
• •Official government statistical agencies track cancer incidence and healthcare spending but do not publish aggregate market size valuations

Rising global cancer incidence driven by aging populations, lifestyle factors, and improved detection rates is the primary demand catalyst. Technological innovation, particularly in liquid biopsy, next-generation sequencing, and artificial intelligence, is accelerating the shift toward minimally invasive and more accurate diagnostics. Growing emphasis on early detection and personalized medicine is expanding both population screening programs and companion diagnostic development.

• •AI in cancer diagnostics represents a rapidly growing segment projected to expand at 26.3% CAGR through 2030
• •Multi-cancer early detection technologies are gaining traction, with the MCED market valued at roughly $1.3 billion in 2025

The market spans multiple technology platforms including imaging, laboratory medicine, molecular diagnostics, and liquid biopsy, with laboratory and pathology services representing the largest share of diagnostic spending. North America leads globally due to advanced healthcare infrastructure, high adoption of new technologies, and significant research activity, while Europe follows as the second-largest market. Asia-Pacific is expected to grow at an accelerated pace driven by improving healthcare access, rising cancer detection rates, and expanding diagnostic infrastructure.

• •North America holds the largest regional market share, supported by favorable reimbursement frameworks and strong R&D activity
• •The Asia-Pacific region is projected as the fastest-growing market due to rising healthcare investments and growing disease burden

What are the recent trends and outlook?

The market outlook is shaped by the convergence of artificial intelligence, liquid biopsy, and multi-cancer early detection technologies. Over the 2025-2030 period, the AI-in-diagnostics and MCED segments are expected to outperform the broader market with significantly higher growth rates. Regulatory approvals, reimbursement expansion, and continued genomic technology cost reductions will determine how quickly these innovations translate into widespread clinical adoption.

• •AI-assisted pathology and radiology are increasingly integrated into routine clinical workflows
• •Multi-cancer early detection blood tests are expected to expand screening access and reduce diagnostic timelines
• •Liquid biopsy adoption continues to grow as a complement to traditional tissue-based diagnostic methods